Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook
Pfizer (NYSE:PFE), a large-cap biopharmaceutical company focused on medicines, vaccines, and specialty therapeutics, closed at $25.21, down 2.74%. This morning's CFO transition announcement and succession review kept investors focused on 2026 guidance and leadership continuity.
The company’s trading volume reached 67.9M shares, which is roughly 85% above its three-month average of 36.6M shares.
How the markets moved today
The S&P 500 (SNPINDEX:^GSPC) rose 1.05% to 7,500.58, while the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 1.91% to 26,518. Among global biopharmaceuticals; research, development, manufacturing, and commercialization of prescription medicines and vaccines, Merck (NYSE:MRK) fell 1.36% to $113.87, and Bristol-Myers Squibb (NYSE:BMY) dropped 2.32% to $54.00.
What this means for investors
Pfizer shares declined after the company announced that CFO Dave Denton will depart in August, raising concerns about leadership continuity and the execution of 2026 guidance. Cecile Guegan will serve as interim CFO during the search for a permanent successor. This transition is significant as Pfizer continues to address patent expirations and ongoing cost-control initiatives.
Recent approvals of Hympavzi and VEPPANU strengthen Pfizer’s long-term pipeline. However, the immediate challenge is maintaining confidence in the 2026 revenue and adjusted EPS targets during the CFO transition. Investors will look for management to provide stable financial guidance and demonstrate that new products, cost controls, and pipeline execution are contributing to earnings recovery.
Should you buy stock in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $415,040!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,256,076!*
Now, it’s worth noting Stock Advisor’s total average return is 920% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 18, 2026.
Eric Trie has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, Merck, and Pfizer. The Motley Fool has a disclosure policy.
Recommended Articles
